For research use only
| Cat No. | ABC-X0030C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocyte |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
The AKT1 (D323H_C310S) BAF3 cell line aids in studying the effects of AKT mutations on cell proliferation, driving the development of new strategies.
Human AKT1 (D323H_C310S) BAF3 Cell Line is a genetically engineered model derived from selected murine Ba/F3 parental cell line based on customers’ requirement. AKT1 (D323H_C310S) BAF3 mutant cell line is generated by stable integration of exogenous human AKT1 gene harboring dual mutations (D323H and C310S) into Ba/F3 host cells using our optimized transduction of lentiviral vectors.
Target
AKT1 is a central serine/threonine kinase involved in cell survival, metabolism, and proliferation via the PI3K/AKT/mTOR pathway. The C310S and D323H mutations are located in the kinase domain and have been associated with altered kinase activity and tumorigenesis. These mutations facilitate the study of structure-function relationships and resistance mechanisms to AKT inhibitors. AcceGen offers generation of stable overexpression and dual-mutant cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0030C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocyte |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO₂ |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
The AKT1 (D323H_C310S) BAF3 Cell Line serves as a powerful tool to investigate altered AKT signaling and therapeutic response. This model enables mechanistic studies of dual mutation effects, IL-3-independent proliferation, and sensitivity to PI3K/AKT pathway inhibitors. It is utilized for oncology drug screening and personalized therapy research.